cleveland.com: Mark Cameron, an infectious disease researcher and associate professor at the School of Medicine, was among the experts who believe a fourth COVID-19 vaccine that’s still in development by Novavax could still play an important role in getting more people vaccinated. “We may be able to reach more people in the U.S. who, for one reason or another, would accept a vaccine that’s a recombinant protein vaccine,” he said. “Maybe they’re just more used to that.”
